Chemokines are relevant molecules in shaping the tumor microenvironment, although their contributions to tumorigenesis are not fully understood. We studied the influence of the chemokine CX3CL1/fractalkine in de novo breast cancer formation using HER2/neu transgenic mice. CX3CL1 expression was downmodulated in HER2/neu tumors, yet, paradoxically, adenovirus-mediated CX3CL1 expression in the tumor milieu enhanced mammary tumor numbers in a dose-dependent manner. Increased tumor multiplicity was not a consequence of CX3CL1-induced metastatic dissemination of the primary tumor, although CX3CL1 induced epithelial-to-mesenchymal transition in breast cancer cells in vitro. Instead, CX3CL1 triggered cell proliferation by induction of ErbB receptors through the proteolytic shedding of an ErbB ligand. This effect was important insofar as mammary tumorigenesis was delayed and tumor multiplicity was reduced by genetic deletion of CX3CL1 in HER2/neu mice, but not in polyoma middle T-antigen oncomice. Our findings support the conclusion that CX3CL1 acts as a positive modifier of breast cancer in concert with ErbB receptors.
Introduction
The development of most solid tumors is intimately linked to external cues provided by the microenvironment (1) . Based mainly on associative studies in human cancers and tumor transplant models, a family of chemotactic proteins termed chemokines has emerged as important molecular regulators of carcinogenesis by shaping the tumor milieu. Most established human tumors produce chemokines, and their expression is associated with poor prognosis (2) . The pro-tumor effects correlate with direct activity on cancer cells, as well as with the regulation of leukocyte and mesenchymal stem cell trafficking into the tumor, which create inflammatory conditions that promote progression of premalignant lesions into malignant neoplasms (2, 3) . Nonetheless, specific chemokines can also exert anti-tumor effects by fostering immune responses that eliminate tumor cells (4, 5) and/or by inhibiting cell transformation and proliferation (6, 7) . These paradoxical results suggest that chemokine function in tumor biology is likely to be tissue-and cell context-dependent. Moreover, the integration of chemokine cues with the complex array of other signals in the tumor environment is usually underestimated. The development of preclinical models that closely recapitulate the evolution of human malignancies would help to clarify the impact of specific chemokines on the biology of individual tumor types.
In a pilot screening for chemokine/chemokine receptor expression in various human primary cancers, we found that CX3CL1, also termed fractalkine, was downmodulated specifically in breast carcinomas compared to adjacent normal tissue (unpublished). This prompted us to study this chemokine and its receptor, CX3CR1, in more detail in breast carcinogenesis.
CX3CR1 expression is reported in different types of cancer cell lines (8, 9) , including those from the breast (10) , where it transduces CX3CL1-induced signals involved in Author Manuscript Published OnlineFirst on May 29, 2013 ; DOI: 10.1158/0008-5472. apparent contradiction, CX3CL1 is a transcriptional target of TP53 (11) , suggesting CX3CL1/CX3CR1 involvement in tumor suppression. Moreover, forced CX3CL1 expression by tumor cells enhances NK-and CD8 + T lymphocyte-mediated anti-tumor immunity (12) (13) (14) . Although these associative studies in human cancers and graft models show a role for CX3CL1/CXC3R1 in tumor biology, to our knowledge no reports have demonstrated an indispensable role for this pair in spontaneous carcinogenesis.
We addressed this question using transgenic FVB/N-Tg(MMTVneu) mice (Tg-neu), which overexpress the proto-oncogene neu (the rat erbB2 orthologue) under the control of the murine mammary tumor virus (MMTV) LTR; these Tg-neu mice develop spontaneous mammary tumors in a stepwise manner, similar to that seen in human ErbB2 + breast tumors.
Increased Her2/ErbB2/Neu expression and activation is linked to the initiation and progression of human cancers, particularly in the breast (15) . ErbB2 tyrosine kinase receptor (RTK) does not bind any known ligand, but amplifies signaling of other ligand-occupied receptors of the same family, Her1/ErbB1/EGFR (epidermal growth factor receptor), Her3/ErbB3 and Her4/ErbB4. There are 11 stimulatory ligands, some of which are expressed as membrane-anchored precursors, with distinct receptor specificity and affinity (16) . These ligands trigger homo-and heterodimerization of ErbB receptors, leading to tyrosine phosphorylation and signal transduction; heterodimerization even enables signaling of the kinase-defective receptor ErbB3.
ErbB receptors can be modulated indirectly by a broad set of heterologous receptors in response to environmental conditions. Cytokine receptors, voltage-gated Ca 2+ channels, integrins, G protein-coupled receptors (GPCR) and Wnt signals induce ErbB receptor transactivation (17, 18) . In some cases, this crosstalk involves direct transphosphorylation by intracellular tyrosine or serine/threonine kinases, causing ErbB receptor activation or endocytosis, respectively (19, 20) . In many cases, the crosstalk involves cleavage of a transmembrane EGF-like precursor, which then activates the receptor in a paracrine/autocrine manner (18, 21) ; this appears to be the mechanism by which CX3CL1 induces ErbB1 transactivation in smooth muscle cells (22) . Transactivation of ErbB receptors could contribute to cancer by integrating distinct signals in the tumor milieu (17) .
Using gain-and loss-of-function approaches, we provide genetic evidence that supports a role for CX3CL1 in mammary carcinoma promotion in Tg-neu mice. CX3CL1 transactivates ErbB receptors in human breast cancer cells and Tg-neu mouse primary mammary gland cultures, leading to the induction of the ERK pathway and cell proliferation. In contrast, CX3CL1 does not influence mammary carcinogenesis in Tg-PyMT mice, in which the ERK signaling pathway is constitutively activated by the mouse polyoma virus middle T-antigen (PyMT) oncogene. We thus propose that CX3CL1 acts as a specific tumor promoter for ErbB2-expressing mammary carcinomas. For mammary tumors, a single tumor mass was used in each experiment. Glands and tumors were digested (16 h, 37ºC) in DMEM/F12 (1:1) with 300 U/ml collagenase/100 U/ml hyaluronidase (Stem Cell Technologies) and gentamicin (50 μg/ml). Digestion was terminated by addition of HBSS (Gibco) with 10 mM HEPES and 2% FCS, and single cell suspensions obtained (25) Calcium mobilization assays were performed as described (27) . Serum-starved (48 h Immunohistochemistry. CX3CL1 was analyzed in cryosections of mouse mammary glands, blocked with 10% BSA in PBS (2 h, 20ºC), followed by incubation (16 h, 4ºC) with anti-CX3CL1 antibodies AF537 (2 μg/ml) or MAB571 (1.1 μg/ml; both from R&D Systems), or sc-7227 (8 μg/ml; Santa Cruz Biotechnology). After incubation with appropriate secondary antibodies (1 h, 20ºC), samples were mounted and observed under a fluorescence microscope (Leica). CX3CR1 was analyzed in mammary tumors and glands using a recombinant hFc-CX3CL1 prepared in our laboratory, followed by biotin-rat anti-hFc antibody and Cy3- Fig. S1 ).
CX3CL1 is downmodulated in breast tumors
We tested CX3CL1/CX3CR1 expression after mammary tumor onset. Most cells isolated from these tumors were CD24 high , which is consistent with the luminal origin of Tg-neu mammary carcinomas; some endothelial and hematopoietic cells also infiltrated these tumors ( Fig. 2A) (Fig. 2B) ; CX3CL1 mRNA was also slightly reduced in endothelial cells isolated from tumors relative to normal tissue. CX3CL1 protein levels were lower in total extracts from tumors vs. normal mammary tissue (Fig. 2C) ; paired analysis of CX3CL1 levels in tumors and healthy mammary glands from the same mice confirmed CX3CL1 downmodulation in carcinomas (Fig. 2D) .
In contrast, CX3CR1 mRNA was upregulated in specific cell populations isolated from tumors; this increase was significant in CD24 high and CD45 + cells, but receptor expression was unaffected in endothelial cells (Fig. 2E) . Fc-CX3CL1 staining showed CX3CR1 expression in tumors and in normal mammary tissue ( Supplementary Fig. S2 ); differences in staining intensity between the two tissues were not evident, as would be predicted by mRNA data.
We analyzed CX3CL1 and CX3CR1 regulation in human breast tumors. Analysis of public data (GEOprofile Database GSE3744, GDS3324; EMBL-EBI Database GEOD10780) from three independent studies (29) (30) (31) showed downregulation of CX3CL1 expression in human primary breast tumors compared to healthy breast tissue (Fig. 2F) . The results for CX3CR1 were not conclusive, since only two of these studies showed a significant reduction in CX3CR1 mRNA in tumor samples (Fig. 2F ). CX3CL1 staining was lower in a small set of in situ and invasive human breast ductal carcinomas compared to non-tumor tissue from the same patient (Fig. 2G, H) . Downmodulation of CX3CL1 expression in Tg-neu tumors might thus be a broad phenomenon in human breast cancer.
CX3CL1 overexpression increases tumor number in Tg-neu mice
Given the anti-tumor activity of CX3CL1 in some cancer models (12) (13) (14) 32) , its downregulation in Tg-neu tumors could be the result of a selection mechanism that silences a potential anti-oncogenic factor. CX3CL1 is produced as a membrane-anchored protein that can be cleaved by specific matrix metalloproteases (MMP); tethered and shed CX3CL1 forms can have different functions (33, 34) . To assess the result of enhanced CX3CL1 expression in the tumor environment, we inoculated Tg-neu mice intratumorally (i.t.) with recombinant adenoviruses to express the full-length (membrane-tethered) CX3CL1 (Ad-CX3CL1) or β-galactosidase (Ad-LacZ). These adenoviruses infected the N202.1A murine mammary cancer cell line (Fig. 3A, B) and the 1g11 mouse endothelial cell line (Fig. 3C, D) , as determined by dose-dependent expression of CX3CL1 mRNA and protein; β-galactosidase activity was also detected in extracts of Ad-LacZ-infected N202.1A cells (Fig. 3B) . These adenoviruses thus transduce the cx3cl1 gene in various cell types in the tumor parenchyma.
As soon as Tg-neu mice presented a palpable lump (75-150 mm 3 ), they received six i.t.
injections of Ad-CX3CL1 or Ad-LacZ. As predicted, Ad-CX3CL1 i.t. injection increased CX3CL1 mRNA levels in tumor (CD24 + ) and endothelial (CD31 + ) cells (Fig. 3E) , as well as serum CX3CL1 levels (Fig. 3F ) compared to those in Ad-LacZ-injected mice. Primary tumors that received injections of Ad-CX3CL1 and Ad-LacZ had similar growth kinetics (Fig. 3G) , and showed no relevant differences in morphology, malignancy score or mitotic figures (Fig. 3H, I ); the tumors were non-infiltrating. Proliferation and apoptosis rates, determined by phospho-histone H3 and TUNEL staining, respectively, were also comparable for Ad-LacZand Ad-CX3CL1-treated tumors ( Supplementary Fig. S3A, B ). There were no apparent differences in the angiogenic pattern between the two tumor groups (Supplementary Fig.   S3C ).
Ad-CX3CL1-treated mice showed a significant increase in the number of mammary glands with palpable tumors compared to those treated with Ad-LacZ (Fig. 3J) . Moreover, mammary glands from treated mice with no macroscopically detectable tumors exhibited microscopic tumors composed of epithelial cells with moderate atypia and some mitoses (Fig. 4A, B) ; these masses did not invade the surrounding stroma and showed no sign of necrosis. Some acini and ductuli near these tumors had normal structure (Fig. 4C) , whereas 
others showed proliferation towards the lumen of epithelial cells with mild atypia (Fig. 4D) ; hyperplastic foci were not always found in the vicinity of tumors (Fig. 4E) We also observed a tendency toward increased multiplicity of palpable tumors in mice that received a single i.t. dose of Ad-CX3CL1, although tumor growth kinetics were unaffected ( Supplementary Fig. S4 ). Elevation of CX3CL1 levels in the tumor environment appears to promote mammary carcinogenesis in Tg-neu mice in a manner dependent on dose and/or duration of exposure.
Lack of lymph node metastases in Ad-CX3CL1-injected mice
Since CX3CL1 can induce metastasis in some models (8, 9) , the Ad-CX3CL1-induced increase in tumor multiplicity could be a result of neoplastic cell dissemination due to chemokine overexpression. Analysis of a collection of human breast cancer cell subtypes with distinct metastatic capacity (35) showed no apparent correlation between CX3CL1 or CX3CR1 mRNA ( Supplementary Fig. S5 ) or protein expression ( Supplementary Fig. S6 ) and the invasive/metastatic potential of the cell lines tested; the untransformed breast epithelial cell line MCF-10A was used as a reference. We also tested whether CX3CL1 could induce epithelia-to-mesenchymal transition (EMT) in breast cancer cells, since EMT is proposed as a (36, 37) . T47D cells, which express CX3CR1 but not its ligand, were infected with Ad-CX3CL1 and Ad-LacZ. Ad-CX3CL1-infected cells showed significantly upregulated mRNA levels of the EMT master gene snail2 (formerly slug) compared to Ad-LacZ-infected cells (Supplementary Fig. S7A ). Increased snail2 expression in Ad-CX3CL1 cells was pertussis toxin (PTx)-sensitive ( Supplementary Fig.   S7B ), indicating that this upregulation was Gα i -mediated. Moreover, CX3CL1 stimulation delocalized E-cadherin from intercellular membranes of T47D cells; this phenotype was partially reversed by co-incubation of CX3CL1 with the N-terminal truncated antagonist Fig. S7F ). The lymphatic vessels are most common route of initial tumor cell dissemination in vivo (38) . Although CX3CL1 induced EMT and enhanced cancer cell motility in vitro, we found no tumor cells in axillary, cervical or inguinal lymph nodes from Ad-CX3CL1-(n = 24) or Ad-LacZ-injected mice (n = 18; Supplementary   Fig. S8 ). We detect no tumor cells in blood or metastases in lung.
CX3CL1 induces transactivation of the EGF pathway
An alternative explanation for the increased tumor multiplicity in Ad-CX3CL1-injected mice is the CX3CL1 potential to stimulate tumor cell expansion, which we studied using T47D cells. [ 3 H]-TdR incorporation assays showed that CX3CL1 alone was a weak mitogen;
nevertheless, it enhanced cell proliferation in the presence of FCS (Fig. 5A ). CX3CL1-induced T47D cell proliferation was inhibited by treatment with AG1478, an inhibitor of ErbB1 kinase activity, or the broad-spectrum MMP inhibitor GM6001 (Fig. 5A ). These To obtain direct evidence that CX3CL1 activates the EGF pathway, we analyzed tyrosine phosphorylation of ErbB receptors in CX3CL1-stimulated T47D cells. These cells express ErbB receptor levels comparable to those in normal breast tissue and do not show ErbB2 amplification (not shown). In this model, CX3CL1 induced ErbB1 phosphorylation, which peaked at 10-30 min post-stimulation (Fig. 5B) ; AG1478 abrogated CX3CL1-induced ErbB1 phosphorylation, indicating that it required the ErbB1 kinase activity (Fig. 5B) .
We then tested the dependence of CX3CL1-triggered signaling pathways on ErbB transactivation. PTx treatment inhibited CX3CL1-mediated Ca 2+ flux (Fig. 5C) , implicating a G i protein in this process. In contrast, CX3CL1-induced ERK1/2 phosphorylation was unaffected by PTx, but was significantly reduced after GM6001 or AG1478 treatment ( Fig. 5D ; Supplementary Fig. S9A ), suggesting the importance of CX3CL1/ErbB crosstalk in the activation of the mitogenic ERK pathway. Neither PTx nor the MMP inhibitors GM6001 or BB94 inhibited AKT phosphorylation ( Fig. 5E ; Supplementary Fig. S9B ), implying that it is independent of ErbB transactivation. It should be noted that T47D cells have mutations in the PI3K pathway (39). Fig. S10 ). To determine which of these ligands is involved in CX3CL1/ErbB crosstalk, T47D cells were stimulated with CX3CL1 in the presence of neutralizing antibodies to amphiregulin, HB-EGF, or TGFα. Each of these antibodies partially inhibited CX3CL1-induced ERK1/2 phosphorylation (Fig. 5F ), suggesting that multiple ErbB ligands are involved in the transactivation circuit.
T47D cells express several membrane-bound EGF family ligands (Supplementary
To determine whether CX3CL1-induced ErbB activation occurs in primary Tg-neu tumors, we stimulated cells from spontaneous carcinomas with CX3CL1, alone or with GM6001 to prevent proteolysis of EGF precursors; phosphorylated ErbB2 levels were then analyzed in total cell extracts. CX3CL1 stimulation of primary tumor cells induced only a slight increase in ErbB2 phosphorylation, which was not inhibited by GM6001 (Fig. 5G) , possibly due to constitutive ErbB2 phosphorylation in the Tg-neu model ( Fig. 5G and (40) ).
We therefore analyzed CX3CL1/ErbB crosstalk in primary mammary epithelium, before transforming ErbB2 mutations occurred. CX3CL1 stimulation of these cultures induced a clear increase in ErbB2 phosphorylation, which was inhibited by GM6001 addition (Fig. 5H) .
These data thus indicated that CX3CL1 triggers ErbB2 transactivation in the preneoplastic mammary epithelium of Tg-neu mice.
CX3CL1 deficiency delays mammary tumor onset in Tg-neu mice
One implication of these results is that CX3CL1 deficiency would affect mammary tumorigenesis in Tg-neu mice. We crossed C57BL/6-CX3CL1 -/-with Tg-neu mice; as C57BL/6-FVB/N-Tg(MMTVneu)-CX3CL1 -/-mice were extremely resistant to mammary cancer (not shown), we backcrossed mice for more than 10 generations on the FVB background. Although C57BL/6-CX3CL1 -/-mice show no overt phenotype (23), ~60% of FVB-Tg-neu-CX3CL1 -/-mice died of causes that remain to be identified; death was not sexassociated. CX3CL1 deficiency did not compromise mammary gland development or architecture, as suggested by the lack of lactation problems in the surviving Tg-neu-CX3CL1 -/-mice and the lack of differences in the structure and cell types composing the mammary gland of mature Tg-neu-CX3CL1 -/-compared to WT mice ( Supplementary Fig.   S11 ).
Analysis of nulliparous Tg-neu-CX3CL1 -/-mice showed a significant delay in mammary tumor onset (Fig. 6A ) and decreased tumor multiplicity (Fig. 6B ) compared to WT mice.
Approximately 30% of Tg-neu-CX3CL1 -/-females had not developed tumors by 15 months of age. Tg-neu-CX3CL1 +/-mice also showed a significant delay in tumor onset (Fig. 6A ) and a decrease in tumor multiplicity (Fig. 6B) Fig. S12 ). Tumors in all three genotypes showed no differences in growth kinetics (Fig. 6C) , again suggesting CX3CL1 involvement only at early stages of mammary carcinogenesis.
The delayed onset and reduced number of mammary tumors in CX3CL1-deficient and hemizygous mice might be linked to the crosstalk between this chemokine and ErbB2. FVBTg(MMTV-PyMT) (Tg-PyMT) mice develop multifocal, aggressive polyclonal tumors at 7-8 weeks of age, due to polyoma middle T-antigen (PyMT) activation of a number of signaling molecules, many of which are shared with ErbB2 (41). We generated CX3CL1-deficient TgPyMT mice; Tg-PyMT-CX3CL1
-/-, -CX3CL1 +/-and WT mice showed no difference in tumor onset (Fig. 6D ) or in mean tumor number per mouse (Fig. 6E ). Tumor growth kinetics was similar for Tg-PyMT-CX3CL1 +/-and WT mice, with a slight reduction in Tg-PyMT-CX3CL1 -/-mice at late stages (Fig. 6F) . These results suggest that the mammary carcinogenesis inhibition associated to reduced CX3CL1 levels depends on ErbB2 
nonetheless unaffected by CX3CL1 deficiency, which concurs with the lack of Ad-CX3CL1 effect on tumor growth. These data suggest that in this model, CX3CL1 promoter activity takes place in early stages of carcinogenesis.
Tumor multiplicity is not comparable between Ad-LacZ-injected (Fig. 3J) and noninjected Tg-neu mice (Fig. 6B) ; this could be a consequence of an injury reaction due to repeated intratumor injection of adenovirus. Such a response could reactivate a low-affinity, neu-specific T cell repertoire in Tg-neu mice (24) , thus partially restricting tumor growth.
This reaction, which would be similar in Ad-LacZ-and Ad-CX3CL1-injected mice, would not occur in non-injected Tg-neu mice.
The mechanism by which CX3CL1 enhances mammary carcinogenesis in Tg-neu mice is not entirely clear. Although CX3CL1 is a proinflammatory chemokine that might promote tumorigenesis by fostering inflammation, histological analyses showed no marked changes in the inflammatory infiltrate associated with CX3CL1 overexpression or deficiency in Tg-neu tumors. Our in vitro results using human breast cancer lines and primary mammary epithelial cells from Tg-neu mice indicate that CX3CL1 enhances cell proliferation by transactivating ErbB receptors. Moreover, CX3CL1 deficiency does not affect tumor onset or multiplicity in Tg-PyMT mice, thus associating CX3CL1-mediated stimulation of mammary carcinogenesis with ErbB2 overexpression and signaling. CX3CR1-ErbB crosstalk is probably not involved in tumor initiation; most mammary tumors in Tg-neu mice have in-frame deletions and insertions of cysteine residues in the ErbB2 extracellular domain, which leads to constitutive receptor dimerization and activation (40) .
Accumulated evidence indicates bidirectional cross-communication between GPCR, the family to which CX3CR1 belongs, and RTK such as ErbB receptors (18, 21, 42) . Although this crosstalk might take place exclusively through intracellular signaling circuits, GPCR usually induce RTK transactivation through an extracellular mechanism involving proteolytic 
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release of the RTK ligand, which binds to and activates the receptor (17, 18) . This "triple passing membrane" signaling usually leads to MAPK pathway activation (18) . The blockade of CX3CL1-mediated cell proliferation and of ERK activation in T47D cells by a general MMP inhibitor indicates that CX3CL1/ErbB crosstalk is controlled by ErbB ligand release from the cell membrane. The specific ligand involved in the transactivation circuit might depend on cell type; for instance, blockade of HB-EGF, amphiregulin, or TGFα inhibited CX3CL1-induced ERK activation in T47D cells.
Analysis of CX3CL1-triggered signaling pathways in breast tumors suggested that ErbB transactivation was specifically needed for CX3CL1-mediated ERK activation, which was unaffected by PTx, but was impaired by the general MMP inhibitor. The ERK pathway induces transcription and secretion of several ErbB ligands (44) , which could create a positive feedback loop that fosters tumor progression. In contrast to ERK, PI3K pathway activation was MMP-independent, suggesting that ErbB transactivation was not involved. In addition, PTx did not inhibit AKT phosphorylation, implying that PI3K activation is Gα i -independent in T47D cells. In smooth muscle cells, CX3CL1-induced ErbB transactivation is implicated in PI3K, but not in ERK activation (22) .
We thus propose a model in which CX3CL1 accelerates the development of incipient neoplastic lesions by enhancing the ERK pathway through ErbB transactivation (Fig. 7) . Such crosstalk would not operate in Tg-PyMT mice, since membrane-bound PyMT directly triggers PI3K and ERK signaling pathways after c-SRC binding and activation (45) phosphorylation of GAB1, an adapter protein involved in ERK signaling (47) . It is tempting to speculate that CX3CL1-induced transactivation causes qualitative and quantitative changes in the strength, frequency and/or adaptation of ERK signaling in transformed mammary cells, conferring a proliferative advantage. Some studies indicate that these ERK signaling parameters affect cell fate decisions (16, 48) .
In summary, we show that CX3CL1 acts as a tumor promoter for the development of spontaneous mouse mammary carcinomas, in models in which ErbB signaling is relevant for tumorigenesis. Our results also highlight the importance of the GPCR-RTK crosstalk in early stages of breast carcinogenesis, which might be extensible to other cancer types (49) . Since the erbB2 gene is amplified in ~30% of human breast tumors, and ~50% of breast cancers overexpress EGFR and EGFRvIII receptors (15, 50) , we propose that the CX3CL1-induced ErbB transactivation reported here operates in human breast cancers, the most common malignancy among women worldwide. 
